Tuesday, September 09, 2008 8:12:59 PM
[After the bell.]Sept. 9, 2008
EDISON, N.J. Hanover Capital Mortgage Holdings, Inc. announced today that on September 5, 2008, the American Stock Exchange notified the Company that it had granted the Company an extension until December 31, 2008 to regain compliance with the continued listing standards of Section 1003(a)(iv) of the Amex Company Guide and until October 8, 2009 to regain compliance with the continued listing standards of Section 1003(a)(i) of the Amex Company Guide.
Previously, on April 8, 2008, the Company received notice from the Amex Staff indicating that the Company was below certain of the Exchange's continued listing standards. Specifically, the notice provided that the Company was not in compliance with (1) Section 1003(a)(i) of the Amex Company Guide due to stockholders' equity of less than $2,000,000 and losses from continuing operations and net losses in two out of its three most recent fiscal years, and (2) Section 1003(a)(iv) of the Amex Company Guide in that the Company had sustained losses which were so substantial in relation to overall operations or its existing financial resources, or its financial condition had become so impaired, that it appeared questionable, in the opinion of the Exchange, as to whether the Company would be able to continue operations and/or meet its obligations as they mature.
The Company was afforded the opportunity to submit a plan of compliance and, on May 8, 2008, submitted its plan to the Exchange. The Exchange did not, at that time, accept the Company's plan, and the Company appealed its decision to the Listing Qualifications Panel, with a scheduled hearing date of August 26, 2008. In support of its position, prior to the hearing, the Company submitted to the Exchange certain supplemental materials in advance of such hearing date. Based on those supplemental materials, the Amex notified the Company on August 25 that it was cancelling the hearing and granting the Company an extension to regain compliance with the continued listing standards.
The Company will be subject to periodic review by Exchange Staff during the extension period. Failure to make progress consistent with the plan and to achieve certain milestones, or to regain compliance with the continued listing standards by the end of the extension period could result in the Company's common stock being delisted from the American Stock Exchange.
Hanover Capital Mortgage Holdings, Inc. is a mortgage REIT staffed by seasoned mortgage capital markets professionals. HCM invests in prime mortgage loans and mortgage securities backed by prime mortgage loans.
For further information, visit HCM's Web site at http://www.hanovercapitalholdings.com.
Recent HCM News
- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 • GlobeNewswire Inc. • 09/17/2024 03:22:47 PM
- HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer • GlobeNewswire Inc. • 09/09/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/30/2024 10:13:25 AM
- HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China • GlobeNewswire Inc. • 08/30/2024 04:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/22/2024 10:10:42 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/21/2024 10:07:52 AM
- HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia • GlobeNewswire Inc. • 08/21/2024 08:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/31/2024 11:13:18 AM
- HUTCHMED Reports 2024 Interim Results and Provides Business Updates • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status • GlobeNewswire Inc. • 07/04/2024 12:00:00 AM
- HUTCHMED to Announce 2024 Half-Year Financial Results • GlobeNewswire Inc. • 06/26/2024 08:30:00 AM
- Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024 • GlobeNewswire Inc. • 06/24/2024 09:30:00 AM
- HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda • GlobeNewswire Inc. • 06/21/2024 08:00:00 PM
- HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology • GlobeNewswire Inc. • 06/17/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/07/2024 10:25:35 AM
- HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China • GlobeNewswire Inc. • 06/07/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/03/2024 10:13:17 AM
- HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine • GlobeNewswire Inc. • 06/03/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/31/2024 10:12:22 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/24/2024 10:06:58 AM
- HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 05/24/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/17/2024 02:02:55 PM
- HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees • GlobeNewswire Inc. • 05/17/2024 02:00:00 PM
- HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress • GlobeNewswire Inc. • 05/17/2024 12:00:00 AM
- HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui • GlobeNewswire Inc. • 05/14/2024 12:00:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM